Y-mAbs Therapeutics (NASDAQ:YMAB) Trading Down 8.3%

Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMABGet Free Report) dropped 8.3% on Monday . The company traded as low as $16.15 and last traded at $16.16. Approximately 37,193 shares were traded during mid-day trading, a decline of 91% from the average daily volume of 432,531 shares. The stock had previously closed at $17.62.

Wall Street Analysts Forecast Growth

YMAB has been the subject of a number of research analyst reports. HC Wainwright raised their price target on Y-mAbs Therapeutics from $21.00 to $22.00 and gave the company a “buy” rating in a research report on Wednesday, March 6th. Canaccord Genuity Group raised their price target on Y-mAbs Therapeutics from $22.00 to $26.00 and gave the company a “buy” rating in a research report on Monday, March 4th. Wedbush restated an “outperform” rating and issued a $18.00 price target (up previously from $12.00) on shares of Y-mAbs Therapeutics in a research report on Monday, February 12th. Finally, BMO Capital Markets raised their price target on Y-mAbs Therapeutics from $16.00 to $26.00 and gave the company an “outperform” rating in a research report on Monday, March 4th. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $16.57.

Read Our Latest Analysis on YMAB

Y-mAbs Therapeutics Stock Down 2.4 %

The firm has a market cap of $704.42 million, a price-to-earnings ratio of -32.84 and a beta of 0.75. The business has a 50 day moving average of $13.08 and a 200 day moving average of $8.27.

Insiders Place Their Bets

In other Y-mAbs Therapeutics news, insider Thomas Gad sold 50,000 shares of the firm’s stock in a transaction dated Friday, December 15th. The stock was sold at an average price of $6.61, for a total value of $330,500.00. Following the sale, the insider now directly owns 265,032 shares of the company’s stock, valued at approximately $1,751,861.52. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In other Y-mAbs Therapeutics news, insider Thomas Gad sold 50,000 shares of the firm’s stock in a transaction dated Friday, December 15th. The stock was sold at an average price of $6.61, for a total value of $330,500.00. Following the sale, the insider now directly owns 265,032 shares of the company’s stock, valued at approximately $1,751,861.52. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, SVP Vignesh Rajah sold 1,711 shares of the firm’s stock in a transaction dated Tuesday, March 5th. The stock was sold at an average price of $16.53, for a total value of $28,282.83. Following the completion of the sale, the senior vice president now directly owns 33,889 shares in the company, valued at $560,185.17. The disclosure for this sale can be found here. 21.50% of the stock is owned by corporate insiders.

Institutional Trading of Y-mAbs Therapeutics

Hedge funds have recently added to or reduced their stakes in the business. Polar Capital Holdings Plc increased its position in Y-mAbs Therapeutics by 108.9% during the 1st quarter. Polar Capital Holdings Plc now owns 2,877,671 shares of the company’s stock worth $34,187,000 after purchasing an additional 1,500,000 shares in the last quarter. Millennium Management LLC increased its position in Y-mAbs Therapeutics by 4,676.0% during the 4th quarter. Millennium Management LLC now owns 1,128,702 shares of the company’s stock worth $5,508,000 after purchasing an additional 1,105,069 shares in the last quarter. State Street Corp increased its position in Y-mAbs Therapeutics by 58.5% during the 1st quarter. State Street Corp now owns 2,308,782 shares of the company’s stock worth $27,428,000 after purchasing an additional 852,112 shares in the last quarter. AQR Capital Management LLC acquired a new stake in Y-mAbs Therapeutics during the 4th quarter worth approximately $2,343,000. Finally, Point72 Asset Management L.P. acquired a new stake in Y-mAbs Therapeutics during the 4th quarter worth approximately $2,193,000. 45.45% of the stock is owned by institutional investors and hedge funds.

About Y-mAbs Therapeutics

(Get Free Report)

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma.

Read More

Receive News & Ratings for Y-mAbs Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Y-mAbs Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.